Pliant Therapeutics PLRX 深 滬
等待開盤 06-04 09:30:00 美东时间
1.195
+0.035
+3.02%
華盛通- 最 高1.20
- 今 開1.18
- 成交量 40.02万股
- 最 低 1.14
- 昨 收 1.16
- 總市值 7399.47万
- 52周最高 1.95
- 市盈率 靜 --
- 換手率 0.65%
- 52周最低 1.09
- 委 比 43.67%
- 總股本 6192.02万
- 歷史最高 43.92
- 量 比 1.06
- 振 幅 5.17%
- 歷史最低 1.09
- 每 手 1
- 風險率 0.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pliant Therapeutics Announces Dosing Of First Participant In FORTIFY Phase 1b Open-Label Indication Expansion Clinical Trial Of PLN-101095 In Combination With Pembrolizumab, In Patients With ICI-Refractory Advanced Or Metastatic Solid Tumors
Pliant Therapeutics (NASDAQ:PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients
04-30 20:33
Pliant Therapeutics Announces Board Retirements and Option Repricing
Pliant Therapeutics ( ($PLRX) ) just unveiled an announcement. Pliant Therapeut...
04-18 05:33
Pliant Therapeutics Launches New $50 Million ATM Program
The latest announcement is out from Pliant Therapeutics ( ($PLRX) ). On March 3...
03-31 06:54
Pliant Therapeutics Presents Data From Phase 1 Trial Of PLN-101095 At AACR Annual Meeting 2026
Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of
03-18 21:03
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics announced the oral presentation of Phase 1 data for PLN-101095 at the AACR Annual Meeting in San Diego. The presentation, titled "First-in-human phase I study of PLN-101095," will be held on April 18, 2026, at 10:21 a.m. PT in Ballroom 6A. PLN-101095 is a dual αvβ8/αvβ1 integrin inhibitor designed to overcome immune checkpoint resistance by targeting TGF-β activation in the tumor microenvironment. The Phase 1 trial evaluates i...
03-18 13:00
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
Pliant Therapeutics GAAP EPS of -$0.38 in-line
Pliant Therapeutics press release (PLRX): Q4 GAAP EPS of -$0.38 in-line. As of December 31, 2025, the Company had cash, cash equivalents and short-term investments of $192.4 million which the Company ...
03-12 04:36
Pliant Therapeutics Q4 EPS $(0.38) Beats $(0.41) Estimate
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.77 percent. This is a 53.66 percent increase over losses of $(0.82) per share
03-12 04:11
